Review
Published on 19 Jul 2023
Recent advances in nanoparticle applications in respiratory disorders: a review
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1059343
- 9,765 views
- 47 citations
Type at least 3 characters
623 articles
Case Report
Published on 17 Jul 2023
Case report: Lung transplantation for treatment of paraquat intoxication: timing of transplantation
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1205689
- 3,157 views
- 7 citations
Editorial
Published on 13 Jul 2023
Editorial: Coronavirus disease (COVID-19): mechanistic basic, translational, and clinical research aimed at identification of effective preventive and therapeutic strategies
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1247765
- 1,084 views
Original Research
Published on 13 Jul 2023
The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1131614
- 2,330 views
- 5 citations
Original Research
Published on 13 Jul 2023
Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1157459
- 4,052 views
- 11 citations
Original Research
Published on 04 Jul 2023
Drug like HSP27 cross linkers with chromenone structure ameliorates pulmonary fibrosis
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1203033
- 3,192 views
- 5 citations
Clinical Trial
Published on 27 Jun 2023
Effects of the Chinese herbal formula San-Huang Gu-Ben Zhi-Ke treatment on stable chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1164818
- 5,013 views
- 2 citations
Original Research
Published on 21 Jun 2023
NRICM101 ameliorates SARS-CoV-2–S1-induced pulmonary injury in K18-hACE2 mice model
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1125414
- 3,694 views
- 5 citations
Original Research
Published on 19 Jun 2023
Inhibition of Nur77 expression and translocation by compound B6 reduces ER stress and alleviates cigarette smoke-induced inflammation and injury in bronchial epithelial cells
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1200110
- 3,463 views
- 8 citations
Original Research
Published on 16 Jun 2023
Elevated serum polyclonal immunoglobulin free light chains in patients with severe asthma
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1126535
- 3,542 views
Review
Published on 15 Jun 2023
Pharmacological approaches to pulmonary fibrosis following COVID-19
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1143158
- 9,723 views
- 15 citations
Correction
Published on 12 Jun 2023
Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1228923
- 1,439 views
Original Research
Published on 09 Jun 2023
Bronchoscopic instillation of amphotericin B is a safe and effective measure to treat pulmonary mycosis
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1167475
- 5,241 views
- 8 citations
Original Research
Published on 02 Jun 2023
Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1178009
- 1,939 views
- 1 citation
Review
Published on 26 May 2023
Landscape analysis and overview of the literature on oxidative stress and pulmonary diseases
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1190817
- 5,196 views
- 14 citations
Review
Published on 23 May 2023
Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1184552
- 13,977 views
- 7 citations